- Home
- CGO vs GNLX Comparison
CGO vs GNLX Comparison
Compare CGO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGO | GNLX |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.4M | 110.4M |
| IPO Year | 2004 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CGO | GNLX |
|---|---|---|
| Price | $12.03 | $2.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.83 |
| AVG Volume (30 Days) | 23.9K | ★ 194.8K |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | ★ 9.25% | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.71 | $2.29 |
| 52 Week High | $14.20 | $8.54 |
Technical Indicators
Market Signals| Indicator | CGO | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 29.84 | 37.92 |
| Support Level | $11.27 | $2.32 |
| Resistance Level | $12.11 | $2.93 |
| Average True Range (ATR) | 0.37 | 0.11 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 5.88 | 4.84 |
Price Performance
Historical ComparisonAbout CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.